BOLDHIGH SIGNALFINANCIAL10-K

BOLD shows severe cash burn with stockholders' equity declining 34.5% to $98.7M and cash dropping 32.8% to $17.9M, while adding new biomarker development and regulatory delay risk factors.

The company is burning through capital at an alarming rate despite reducing R&D spending by 18.9%, with total assets shrinking nearly 24% year-over-year. The addition of specific risk factors around biomarker identification challenges and regulatory delays suggests management is acknowledging significant execution risks that could further impair the company's ability to achieve commercialization milestones.

Comparing 2026-03-09 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

BOLD's financials show a company under severe capital strain, with stockholders' equity plummeting 34.5% and cash reserves dropping 32.8% to just $17.9M despite cutting R&D expenses by nearly 19%. While operating cash flow improved modestly and operating losses narrowed by 13.3%, the company burned through nearly $49M in total assets, indicating an unsustainable trajectory. Current liabilities spiked 54.1%, further constraining liquidity and suggesting potential near-term funding pressures for this clinical-stage biotech.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-78.5%
$2.5M→$546K

Capex reduced 78.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+54.1%
$8.1M→$12.5M

Current liabilities surged 54.1% — significant near-term obligations; verify ability to meet short-term debt.

Stockholders Equity
Balance Sheet
-34.5%
$150.6M→$98.7M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-32.8%
$26.6M→$17.9M

Cash declined 32.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-29%
$154.4M→$109.6M

Current assets declined 29% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-23.9%
$206.4M→$157.1M

Total assets contracted 23.9% — asset sales, write-downs, or balance sheet optimization underway.

Operating Cash Flow
Cash Flow
+23.3%
-$60.8M→-$46.7M

Operating cash flow grew 23.3% — strong conversion of earnings to cash, healthy business fundamentals.

R&D Expense
P&L
-18.9%
$55.3M→$44.8M

R&D spending cut 18.9% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+13.3%
-$73.3M→-$63.6M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+11%
-$65.4M→-$58.2M

Net income grew 11% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-27
ADDED
RISK FACTORS SUMMARY Below is a summary of the principal factors that make an investment in our common stock speculative or risky.
If we are unable to successfully identify predictive biomarkers to identify patient populations most likely to benefit from our ecDTx, or develop a diagnostic to enable patient selection for our ecDTx, or if we experience significant delays in doing so, we may not realize the full commercial potential of our ecDTx.
Interim, topline, and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
We rely on third parties to conduct our clinical trials and preclinical studies, manufacture our ecDTx, package, label, ship, store, and distribute our ecDTx, and supply products used as combination agents in our clinical trials, and these third parties may not perform satisfactorily or at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.
Securities and Exchange Commission (SEC), and other government agencies, including due to government shutdowns, other funding shortages, policy changes, leadership changes, layoffs or significant personnel turnover, or public health concerns could impede development and potential marketing approval of our ecDTx and our ability to raise capital.
+7 more — sign up free →
REMOVED
In addition, while we are responsible for all of the disclosure contained in this report and we believe the industry, market, and competitive position data included in this report is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed below under the section titled Risk Factors Summary and in Part I, Item 1A, Risk Factors.
All of our other ecDTx programs are still in the preclinical or discovery stage.
If we are unable to successfully develop an ecDNA diagnostic to enable patient selection for our ecDTx, or if we experience significant delays in doing so, we may not realize the full commercial potential of our ecDTx.
The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.
Our lead ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages replication stress associated with gene amplification in cancer cells.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →